Education
About Us
Working with TipRanks
Follow Us
Kineta, Inc. (KANT)
OTHER OTC:KANT
KANT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.18 - $1.15
Previous CloseN/A
Volume280.00
Average Volume (3M)18.68K
Market Cap
$4.55M
Enterprise Value$6.85M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding51,099,000
10 Day Avg. Volume6,928
30 Day Avg. Volume18,681
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kineta News
KANT FAQ
What was Kineta, Inc.’s price range in the past 12 months?
Kineta, Inc. lowest stock price was $0.18 and its highest was $1.15 in the past 12 months.
What is Kineta, Inc.’s market cap?
Kineta, Inc.’s market cap is $4.55M.
When is Kineta, Inc.’s upcoming earnings report date?
Kineta, Inc.’s upcoming earnings report date is May 08, 2025 which is 93 days ago.
How were Kineta, Inc.’s earnings last quarter?
Currently, no data Available
Is Kineta, Inc. overvalued?
According to Wall Street analysts Kineta, Inc.’s price is currently Overvalued.
Does Kineta, Inc. pay dividends?
Kineta, Inc. does not currently pay dividends.
What is Kineta, Inc.’s EPS estimate?
Kineta, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kineta, Inc. have?
Kineta, Inc. has 51,099,000 shares outstanding.
What happened to Kineta, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kineta, Inc.?
Currently, no hedge funds are holding shares in KANT
Company Description
Kineta, Inc.
Kineta, Inc. (KANT) is a clinical-stage biotechnology company focused on developing novel therapies in the immuno-oncology sector. The company's core products include innovative treatments aimed at enhancing the immune system's ability to combat cancer. Utilizing advanced immunotherapeutic approaches, Kineta seeks to address critical unmet needs in oncology, offering potential breakthroughs in cancer treatment.
Kineta (KANT) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Cyclacel Pharmaceuticals
―
Brainstorm Cell Therapeutics
―
ESSA Pharma
―
Kura Oncology
―
BioVie
―
Galera Therapeutics
―
Ownership Overview
19.85% Insiders
<0.01% Mutual Funds
3.04% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---